Skip to main content
Have a personal or library account? Click to login
Dissolution profiles of perindopril and indapamide in their fixed-dose formulations by a new HPLC method and different mathematical approaches Cover

Dissolution profiles of perindopril and indapamide in their fixed-dose formulations by a new HPLC method and different mathematical approaches

Acta Pharmaceutica
Volume 65 (2015): Issue 3 (September 2015)
By: ,  ,   and    
Open Access
|Sep 2015
References

References

  1. 1. M. Gorostidi and A. De la Sierra, A combination therapy in hypertension,(2013) 320–336; DOI: 10.1007/s12325-013-0020-9.
    Open DOISearch in Google Scholar
  2. 2. D.K. Modi and C.N. Patel, Development and validation of spectrophotometric method for simultaneous estimation of perindopril and indapamide in combined dosage form by simultaneous equation,.(2011) 46–52.
    Search in Google Scholar
  3. 3. S.S. Kale, R.L. Bakal, A.V. Chandewar and R.S. Sakhare, Two wavelength method for estimation of indapamide and perindopril erbumine in combined tablet dosage form,(2011) 545–548.
    Search in Google Scholar
  4. 4. D.K. Modi and C.N. Patel, Development and validation of spectrophotometric method for simultaneous estimation of perindopril and indapamide in combined dosage form by absorbance correction method,(2010) 411–416.
    Search in Google Scholar
  5. 5. N. Erk, Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations,(2001) 43–45; DOI: 10.1016/S0731-7085(01)00388-0.
    Open DOISearch in Google Scholar
  6. 6. R. Tiwan, A. Jain, D. Maliwal and E. Toppo, Multicriteria optimization methodology in development of HPLC method for simultaneous estimation of indapamide and perindopril in bulk drug and its combined dosage form,(2012) 50–53.
    Search in Google Scholar
  7. 7. J. Joseph, B. Philip and M. Sundarapandian, Method development and validation for simultaneous estimation of perindopril erbumine and indapamide by RP-HPLC in pharmaceutical dosage forms,.(2011) 288–293.
    Search in Google Scholar
  8. 8. H. Jogia, U. Khandelwal, T. Gandhi, S. Singh and D. Modi, Development and validation of a stability-indicating assay method for simultaneous determination of perindopril and indapamide in combined dosage form by reversed-phase high-performance liquid chromatography,(2010) 108–115.
    Open DOISearch in Google Scholar
  9. 9. A. A. Elshanawane, S. M. Mostafa and M. S. Elgawish, Development and validation of LC method for simultaneous determination of two binary mixtures containing indapamide,(2008) 837–840; DOI: 10.1365/s/10337-008-0600-z0009-5893/08/05.
    Search in Google Scholar
  10. 10. C. Graffner, Regulatory aspects of drug dissolution from a European perspective,(2006) 288–293; DOI: 10.1016/j.ejps.2006.05.003.
    Open DOISearch in Google Scholar
  11. 11. T. O′Hara, A. Dunne, J. Butler and J. Devane, A review of methods used to compare dissolution profile data,.(1998) 214–223; DOI: 10.1016/S1461-5347(98)00053-4.
    Open DOISearch in Google Scholar
  12. 12. P. Costa and J. M. S. Lobo, Modeling and comparison of dissolution profiles,(2001) 123–133; DOI: 10.1016/S0928-0987(01)00095-1.
    Open DOISearch in Google Scholar
  13. 13. N. Yuksel, A. E. Kanik and T. Baykara, Comparison ofdissolution profiles by ANOVA-based, model dependent and –independent methods,.(2000) 57–67; DOI: 10.1016/S0378-5173(00)00554-8.
    Open DOISearch in Google Scholar
  14. 14. R. M. Maggio, P. M. Castellano and T. S. Kaufman, A new principal component analysis-based approach for testing “similarity” of drug dissolution profiles,(2008) 66–77; DOI: 10.1016/j.ejps.2008.02.009.
    Open DOISearch in Google Scholar
  15. 15. European Medicines Agency,, EMA CPMP/EWP/QWP/1401/98, July 2001;; access date April 10, 2015.
    Search in Google Scholar
  16. 16. Food and Drug Administration,:U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), FDA, August 1997.; last access date June 27, 2014.
    Search in Google Scholar
  17. 17. E. Adams, R. De Maesschalck, B. De Spiegeleer, Y. Vander Heyden, J. Smeyers-Verbeke and D. L. Massart, Evaluation of dissolution profiles using principal component analysis,.(2001) 41–53; DOI: 10.1016/S0378-5173(00)00581-0.
    Open DOISearch in Google Scholar
  18. 18, EDQM Council of Europe, Strasbourg 2010.
    Search in Google Scholar
  19. 19. Y. Zhang, H. Meirong, J. Zhou, A. Zou, W. Li, W. Yao and S. Xie, DDSolver: an add-in program for modeling and comparison of drug dissolution profiles,(2010) 263–271; DOI: 10.1208/s12248-010-9185-1.
    Open DOISearch in Google Scholar
  20. 20. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use,, Currentversion, November 2005;; last access date April 15, 2014.
    Search in Google Scholar
  21. 21. The United States Pharmacopoeia USP 34, NF 29, USP Convention, Rockville 2011.
    Search in Google Scholar
DOI: https://doi.org/10.1515/acph-2015-0024 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 235 - 252
Accepted on: May 14, 2015
Published on: Sep 30, 2015
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
perindopril,
indapamide,
dissolution profiles,
model-independent methods,
model-dependent methods,
PCA
Related subjects:
Pharmacy,
Pharmacy, other

© 2015 Anna Gumieniczek, Paulina Mączka, Łukasz Komsta, Rafał Pietraś, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 65 (2015): Issue 3 (September 2015)
Previous article
Next article